May 2, 2024 | Access, clinical trials, digital health, digital tools, oncology, patient insight-gathering, reimbursement
With rapid growth comes growing pains…

The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). However, with rapid growth comes growing pains.
New competitors are entering the market at a rapid pace, and competition is intensifying. There are currently more than 2,000 oncology products under development. Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017). This competitive intensity tends to focus on smaller patient populations with multiple treatment options.
With a larger number of treatable patients, improving survival rates, more clinical trials, and increased focus on real-world evidence, the definition of ‘standard of care’ is continuously changing. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers.
Further, the time advantage traditionally afforded to new cancer therapies has been substantially reduced due to advances in our understanding of the underlying tumor biology and the emergence of novel treatment modalities. Occasionally, the advantage disappears well before the period of exclusivity ends (2)…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson’s community catalyzed the founding of Charco and how innovative medical devices and software can improve…
Although many people are starting to go back to their offices, at least for part of the week, many others are looking at permanent ‘Work From Home’ (WFH) set-ups. At…
I’m excited to share another Impetus top-10 list! This time, I focus on the top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory…
Dvorah Richler, Head of Soaring with Roche, and Michael Duong, Head of Innovation at Michael Duong, discuss the 5 healthcare challenges that Soaring with Roche aims to solve through innovative…
In this article, we dive into the world of hybrid meetings, including the different definitions of “hybrid,” the importance of over-time engagement, and more.
We recently shared our top-10 creative ways to engage your advisors and most important advisor questions. In Impetus Digital’s third top-10 list, we focus on how to optimize asynchronous virtual…
Alex Gilbert, Head of Digital Medicines Development & Life Sciences Partnerships at Huma, explores virtual & decentralized trials, digital biomarkers, digital-first delivery of care, at-home hospitals, and many other thought-provoking…
While Pharma was already slowly pivoting towards virtual events as a substitute for, or supplement to, in-person meetings, COVID-19 quickly changed virtual events from a nice-to-have to a must. With…
Dr. Patrick Carroll, Chief Medical Officer at Vida Health, discusses the importance of using a “whole health” approach to chronic disease management, how and why the human connection with a…
No matter which sector you work in, diversity and inclusion are must-haves!
